Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab
Open Access
- 3 March 2011
- journal article
- case report
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 127 (3), 841-844
- https://doi.org/10.1007/s10549-011-1417-2
Abstract
Trastuzumab, a monoclonal antibody against the HER2 receptor, is a major breakthrough in the treatment of HER2+ breast cancer. However, its high molecular weight precludes it from crossing the intact blood–brain barrier, making the central nervous system a sanctuary to HER2+ breast cancer metastases. We prospectively assessed functional outcome and toxicity of administering trastuzumab directly into the cerebrospinal fluid of a patient with leptomeningeal carcinomatosis (LC) and brain metastases from HER2+ breast cancer that had already been treated with other intrathecal chemotherapy, with no benefit. Upon signed informed consent, weekly lumbar puncture with administration of trastuzumab 25 mg was begun to a 44 year-old women with metastatic breast cancer (lymph node, bone, lung, and liver involvement) previously treated with tamoxifen, letrozole, anthracyclines, taxanes, capecitabine, intravenous trastuzumab, and lapatinib. She received 67 weekly administrations of intrathecal trastuzumab with marked clinical improvement and no adverse events. She survived 27 months after LC diagnosis. A complete leptomeningeal response, with no evidence of leptomeningeal metastasis at necropsy, was achieved. We believe that intrathecal trastuzumab administration should be prospectively evaluated to confirm clinical activity and optimize dose, schedule, and duration of treatment.Keywords
This publication has 14 references indexed in Scilit:
- Disruption of the blood brain barrier by brain metastases of triple‐negative and basal‐type breast cancer but not HER2/neu‐positive breast cancerCancer, 2009
- Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancerAnnals of Oncology, 2009
- High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancerAnnals of Oncology, 2008
- Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case reportAnti-Cancer Drugs, 2008
- Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrierAnti-Cancer Drugs, 2007
- Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumabThe Lancet Oncology, 2006
- Adjuvant Trastuzumab: A Milestone in the Treatment of HER-2-Positive Early Breast CancerThe Oncologist, 2006
- Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)Annals of Oncology, 2006
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Leptomeningeal carcinomatosisCancer Treatment Reviews, 1999